These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

433 related items for PubMed ID: 28244643

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system.
    Albertsen BK, Schrøder H, Ingerslev J, Jakobsen P, Avramis VI, Müller HJ, Carlsen NT, Schmiegelow K.
    Br J Haematol; 2001 Dec; 115(4):983-90. PubMed ID: 11843837
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group.
    Salzer WL, Asselin B, Supko JG, Devidas M, Kaiser NA, Plourde P, Winick NJ, Reaman GH, Raetz E, Carroll WL, Hunger SP.
    Blood; 2013 Jul 25; 122(4):507-14. PubMed ID: 23741010
    [Abstract] [Full Text] [Related]

  • 6. Monitoring of Erwinia asparaginase therapy in childhood ALL in the Nordic countries.
    Albertsen BK, Schrøder H, Jakobsen P, Müller HJ, Carlsen NT, Schmiegelow K.
    Br J Clin Pharmacol; 2001 Oct 25; 52(4):433-7. PubMed ID: 11678787
    [Abstract] [Full Text] [Related]

  • 7. Antibody formation during intravenous and intramuscular therapy with Erwinia asparaginase.
    Albertsen BK, Schrøder H, Jakobsen P, Avramis VI, Müller HJ, Schmiegelow K, Carlsen NT.
    Med Pediatr Oncol; 2002 May 25; 38(5):310-6. PubMed ID: 11979454
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Asparaginase Erwinia chrysanthemi (Erwinaze®): a guide to its use in acute lymphoblastic leukemia in the USA.
    Keating GM.
    BioDrugs; 2013 Aug 25; 27(4):413-8. PubMed ID: 23794007
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Cerebrospinal fluid asparagine concentrations after Escherichia coli asparaginase in children with acute lymphoblastic leukemia.
    Woo MH, Hak LJ, Storm MC, Gajjar AJ, Sandlund JT, Harrison PL, Wang B, Pui CH, Relling MV.
    J Clin Oncol; 1999 May 25; 17(5):1568-73. PubMed ID: 10334545
    [Abstract] [Full Text] [Related]

  • 15. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.
    Rau RE, Dreyer Z, Choi MR, Liang W, Skowronski R, Allamneni KP, Devidas M, Raetz EA, Adamson PC, Blaney SM, Loh ML, Hunger SP.
    Pediatr Blood Cancer; 2018 Mar 25; 65(3):. PubMed ID: 29090524
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Higher plasma asparaginase activity after intramuscular than intravenous Erwinia asparaginase.
    Panetta JC, Liu Y, Swanson HD, Karol SE, Pui CH, Inaba H, Jeha S, Relling MV.
    Pediatr Blood Cancer; 2020 Jul 25; 67(7):e28244. PubMed ID: 32323890
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.